Acro Biomedical Co., Ltd.
ACBM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$360 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $296 |
| Gross Profit | $0 | $0 | $0 | -$64 |
| % Margin | – | – | – | 17.8% |
| R&D Expenses | $0 | $0 | $0 | $6,918 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $115 | $14 | $9 | $4,240 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$11,149 |
| Operating Expenses | $115 | $14 | $9 | $9 |
| Operating Income | -$115 | -$14 | -$9 | -$9 |
| % Margin | – | – | – | 2.6% |
| Other Income/Exp. Net | -$3 | -$2 | -$1 | -$1 |
| Pre-Tax Income | -$118 | -$16 | -$10 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$118 | -$16 | -$10 | -$11 |
| % Margin | – | – | – | 3% |
| EPS | -0.002 | -0 | -0 | 0.18 |
| % Growth | -566.7% | -50% | -100.1% | – |
| EPS Diluted | -0.002 | -0 | -0 | 0.18 |
| Weighted Avg Shares Out | 60,042 | 60,042 | 60,042 | 60,042 |
| Weighted Avg Shares Out Dil | 60,042 | 60,042 | 60,042 | 60,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $2 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$115 | -$14 | -$9 | -$9 |
| % Margin | – | – | – | 2.6% |